CTLA4 and melanoma: A cocktail of the broad-spectrum antibiotics ampicillin, colistin, and streptomycin, as well as the beta-lactam imipenem alone, were found to compromise the anticancer effect of the anti-CTLA-4 therapy in mouse models of sarcoma, melanoma, and colon cancer [31].